The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer

Journal for ImmunoTherapy of Cancer

Paolo A. Ascierto¹  Sabino De Placido⁷  Vincenzo Montesarchio⁴  Giacomo Cartenì⁵  Fabio Calabrò⁶  Daniel Petrylak⁸  Bruno Sangro²  Bruno Daniele³ 

[1] Unit of Melanoma, Cancer Immunotherapy and Innovative Therapies, Istituto Nazionale Tumori Fondazione “G. Pascale”, Via Mariano Semmola, Naples, 80131, Italy;Liver Unit, Clinica Universidad de Navarra, IDISNA and CIBEREHD, Pamplona, Spain;Department of Oncology, A.O. “G. Rummo”, Benevento, Italy;Unit of Oncology, A.O.R.N. dei COLLI “Ospedali Monaldi-Cotugno-CTO”, Naples, Italy;Unit of Medical Oncology, Dipartimento di Oncopneumoematologia, A.O.R.N. “A. Cardarelli”, Naples, Italy;San Camillo-Forlanini Hospital, Rome, Italy;Department of Molecular and Clinical Endocrinology and Oncology, University “Federico II”, Naples, Italy;Genitourinary Oncology Research Program, Yale Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, USA

关键词: Solid tumors;    Peptide vaccines;    Cell-based vaccines;    Checkpoint inhibitors;    Immunotherapy;   

Others  :  1235588
DOI  :  10.1186/s40425-015-0105-x

 received in 2015-11-02, accepted in 2015-12-29,  发布年份 2016

【 摘 要 】

In this paper, we review recent advances in immuno-oncology with particular focus on liver, kidney, and bladder cancers as discussed at the 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO).

【 授权许可】

   
2016 Daniele et al.

【 参考文献 】

• [1]Vesely MD, Kershaw MH, Schreiber RD. Natural innate and adaptive immunity to cancer. Ann Rev Immunol. 2011; 29:235-271.
• [2]Ascierto PA, Addeo R, Cartenì G, Daniele B, De Laurentis M, Ianniello GP et al.. The role of immunotherapy in solid tumors: report from the Campania Society of Oncology Immunotherapy (SCITO) meeting, Naples 2014. J Transl Med. 2014; 12:291. BioMed Central Full Text
• [3]Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C et al.. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15:7412-7420.
• [4]Lipson EJ, Sharfman WH, Drake CG, Wollner I, Taube JM, Anders RA et al.. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2013; 19:462-468.
• [5]Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al.. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363:711-723.
• [6]Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA et al.. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015; 33:2004-2012.
• [7]Yoong KF, Afford SC, Jones R, Aujla P, Qin S, Price K et al.. Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology. 1999; 30:100-111.
• [8]Wada Y, Nakashima O, Kutami R, Yamamoto O, Kojiro M. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998; 27:407-414.
• [9]Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS et al.. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol. 2007; 25:2586-2593.
• [10]Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y et al.. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res. 2009; 15:971-979.
• [11]Tarhini AA. Tremelimumab: a review of development to date in solid tumors. Immunotherapy. 2013; 5:215-229.
• [12]Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P et al.. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 2013; 59:81-88.
• [13]Duffy AG, Makarova-Rusher OV, Kerkar SP, Kleiner DE, Fioravanti S, Walkeret M, et al. A pilot study of tremelimumab – a monoclonal antibody against CTLA-4 – in combination with either trans catheter arterial chemoembolization (TACE) or radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2015;33 (suppl; abstr 4081).
• [14]Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S et al.. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res. 2013; 19:6151-6162.
• [15]Bockorny B, Dasanu CA. Intrinsic immune alterations in renal cell carcinoma and emerging immunotherapeutic approaches. Expert Opin Biol Ther. 2013; 13:911-925.
• [16]McDermott DF. Immunotherapy of metastatic renal cell carcinoma. Cancer. 2009; 115(10 Suppl):2298-2305.
• [17]Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C et al.. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med. 2012; 18:1254-1261.
• [18]Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C et al.. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010; 16:5539-5547.
• [19]Amin A, Dudek AZ, Logan TF, Lance RS, Holzbeierlein JM, Knox JJ et al.. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results. J Immunother Cancer. 2015; 3:14. BioMed Central Full Text
• [20]Drake CG, McDermott DF, Sznol M, Choueiri TK, Kluger HM, Powderly JD, et al. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): Long-term patient follow-up. J Clin Oncol 2013;31(suppl; abstr 4514)
• [21]Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR et al.. Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. J Clin Oncol. 2015; 33:1430-1437.
• [22]Choueiri TK, Fishman MN, Escudier BJ, Kim JJ, Kluger HM, Stadler WM, et al. Immunomodulatory activity of nivolumab in previously treated and untreated metastatic renal cell carcinoma (mRCC): Biomarker-based results from a randomized clinical trial. J Clin Oncol 2014; 32:5s (suppl; abstr 5012).
• [23]Hammers HJ, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF et al.. Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014; 32(suppl; abstr 4504):5s.
• [24]Amin A, Plimack ER, Infante JR, Ernstoff MS, Rini BI, McDermott DF et al.. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2014; 32(suppl; abstr 5010):5s.
• [25]Zhang J, Dickinson SI, Clark ND, Flaherty AL. Expression of PD-L1 in primary urothelial carcinoma (UC). J Clin Oncol 2013;31 (suppl; abstr 4541)
• [26]Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria JC, Hamid O, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol 2013;31 (suppl; abstr 3000)
• [27]Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Zambrano CC, et al. A phase Ia study of MPDL3280A (anti-PDL1): Updated response and survival data in urothelial bladder cancer (UBC). J Clin Oncol 2015;33 (suppl; abstr 4501)
• [28]O’Donnell PH, Plimack ER, Bellmunt J, Berger R, Montgomery RB, Heath K, et al. Pembrolizumab (Pembro; MK-3475) for advanced urothelial cancer: Results of a phase IB study. J Clin Oncol 2015;33 (suppl 7; abstr 296)